Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences

    BioCentury Newsmakers in the Biotech Industry
    Thursday, September 4, 2008, 10:00 AM Eastern time
    Millennium Broadway Hotel, New York

    UBS Global Life Sciences Conference
    Tuesday, September 23, 2008, 9:30 AM Eastern time
    Grand Hyatt Hotel, New York

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

SOURCE Orexigen Therapeutics

Copyright © 2009, PRNewswire
newsblaze
Copyright © 2009, NewsBlaze, Daily News

Tags: ,HEA,MTC,BIO,TDS,CA-Orexigen(R)

   _   _

           

Is your favorite bookmark site missing? Ask for it.